Description

Gaudium IVF and Women Health Limited (ticker: 544709) will be added to the BSE IPO Index effective March 4, 2026, following its listing on BSE on February 27, 2026.

Summary

BSE Index Services Private Limited has announced the addition of Gaudium IVF and Women Health Limited (Exchange Ticker: 544709) to the BSE IPO Index. The stock was listed on BSE on February 27, 2026, and will be included in the index effective at the open of March 4, 2026.

Key Points

  • Gaudium IVF and Women Health Limited (ticker: 544709) listed on BSE on February 27, 2026
  • The stock will be added to the BSE IPO Index effective at the open on March 4, 2026
  • The corporate action is included in the end-of-day corporate action file (*.SDE) dated February 27, 2026
  • Reference is made to prior Notice No. 20260226-41 regarding the listing

Regulatory Changes

No regulatory changes. This is a routine index rebalancing action by BSE Index Services Private Limited following the IPO listing of a new constituent.

Compliance Requirements

  • Index fund managers and ETF providers tracking the BSE IPO Index must incorporate the addition of ticker 544709 effective March 4, 2026
  • Clients with queries are directed to contact bseindex@bseindia.com

Important Dates

  • February 27, 2026: Listing date of Gaudium IVF and Women Health Limited on BSE
  • February 27, 2026: End-of-day corporate action file (*.SDE) updated with this action
  • March 4, 2026: Effective date of addition to the BSE IPO Index (at market open)

Impact Assessment

The impact is limited to passive investors and funds tracking the BSE IPO Index. Fund managers benchmarked to this index will need to rebalance their portfolios to include ticker 544709 before the market open on March 4, 2026. There is no broader market or regulatory impact from this routine index constituent addition.

Impact Justification

Routine index constituent addition following a new IPO listing; affects index tracking funds and passive investors benchmarked to the BSE IPO Index but has no broader regulatory or compliance implications.